Extracellular Vesicles, Liposomes, and Hybrid Nanovesicles: Comparative Strategies for Targeted Cancer Therapy

Area of Science:

• Nanomedicine
• Oncology
• Biotechnology

Background:

• Liposomes and extracellular vesicles (EVs) are nanoscale drug delivery systems used in cancer therapy.
• Liposomes offer versatility and scalability but face challenges with tumor heterogeneity and drug release.
• EVs provide biocompatibility and targeting but have limitations in loading capacity and manufacturing.

Purpose of the Study:

• To explore hybrid nanovesicles integrating EVs and liposomes for improved cancer drug delivery.
• To leverage the complementary advantages of both EVs and liposomes in a single nanocarrier system.
• To enhance tumor targeting, therapeutic efficacy, and payload diversity for cancer treatment.

Main Methods:

• Development of hybrid EV-liposome nanovesicles.
• Integration of synthetic (liposome) and biological (EV) components.
• Evaluation of enhanced tumor targeting, therapeutic efficacy, and payload delivery.

Main Results:

• Hybrid nanovesicles combine the strengths of both EVs and liposomes.
• Improved tumor targeting and enhanced therapeutic efficacy observed in preclinical studies.
• Potential for diverse payload delivery, including drugs and nucleic acids.

Conclusions:

• Hybrid EV-liposome nanovesicles represent a promising platform for next-generation cancer nanomedicine.
• These strategies address key limitations of current delivery systems, improving therapeutic index.
• Advancing clinical translation by overcoming challenges in scalability, standardization, and in vivo understanding.